Device Trial Radar · NCT05627076
Analytical Validation of the abioSCOPE Device With the IVD CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood.
Last checked: Nov 19, 2026Latest source record: Nov 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Aug 29, 2022
Primary completion
Oct 11, 2022
Study completion Oct 31, 2022
Sponsor
- Lead sponsor
- Abionic SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 25, 2022
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Abionic has developed a targeted, rapid test for pancreatic stone protein (PSP) in human K2-EDTA venous whole blood using the abioSCOPE instrument. Currently no PSP study comparaison has been done between venous and arterial whole blood. Abionic would like to confirm the equivalence of the PSP between venous whole blood and arterial whole blood.
Conditions
- Sepsis
- Sepsis Bacterial
Interventions
Blood SamplingDevice
Blood samples will be collected for the PSP measurement using the abioSCOPE.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary assessmentTime frame: through study completion, an average of 1.5 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Limoges, Réanimation Polyvalente
Limoges, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.